Polyrizon Rebrands Allergy Blocker as NASARIX™, Aims for Drug-Free Market Disruption — MR Solutions Limited

Event summary

Polyrizon Ltd. (Nasdaq: PLRZ) rebranded its lead intranasal allergy product from PL-14 to NASARIX™ in February 2026, completing trademark screening in the U.S. and European markets.
NASARIX™ uses Capture and Contain™ hydrogel technology to form a bio-adhesive barrier that physically traps allergens before they reach nasal tissue.
The global allergic rhinitis treatment market is valued at USD 13.08 billion in 2025, projected to reach USD 18.81 billion by 2035 at a CAGR of 3.7%.
Polyrizon initiated a human factors and usability study on January 22, 2026, with clinical trials expected to begin in Q3 2026.

The big picture

Polyrizon's NASARIX™ targets a growing market for non-pharmacological allergy solutions, leveraging a drug-free approach that could appeal to users seeking natural, preventive protection. The company's strategic focus on a medical device pathway aims to expedite regulatory approval and market entry, potentially disrupting the allergic rhinitis treatment landscape. The success of NASARIX™ will hinge on its ability to demonstrate superior allergen-blocking capabilities and user comfort in upcoming clinical trials.

What we're watching

Clinical Trial Outcomes: Whether NASARIX™ can confirm its preclinical efficacy and safety in human trials starting later in 2026.
Regulatory Pathway: The pace at which Polyrizon can navigate the FDA approval process for NASARIX™ as a medical device.
Market Adoption: How NASARIX™ will position itself against existing allergy treatments in a USD 13.08 billion market.